Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity
- journal article
- review article
- Published by Wolters Kluwer Health
- Vol. 169 (1) , 90-95
- https://doi.org/10.1016/s0022-5347(05)64043-8
Abstract
We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-Guerin (BCG) with mitomycin C on recurrence of stages Ta and T1 bladder carcinoma. Combined published and unpublished data from comparative studies on BCG versus mitomycin C for superficial bladder carcinoma considering possible confounding factors were analyzed. Odds ratio (OR) and its 95% CI were used as primary effect size estimate. Toxicity data were evaluated descriptively. In 11 eligible clinical trials 1,421 patients were treated with BCG and 1,328 were treated with mitomycin C. Within the overall median followup time of 26 months 38.6% of the patients in the BCG group and 46.4% of those in the mitomycin C group had tumor recurrence. In 7 of 11 studies BCG was significantly superior to mitomycin C, in 3 studies no significant difference was found, while in 1 study mitomycin C was significantly superior to BCG. An overall statistically significant superiority of BCG versus mitomycin C efficacy in reducing tumor recurrence was detected (OR 0.56, 95% CI 0.38 to 0.84, p = 0.005). In the subgroup treated with BCG maintenance all 6 individual studies showed a significant superiority of BCG over mitomycin C (OR 0.43, 95% CI 0.35 to 0.53, p <0.001). In 4 of the 5 studies with reported data on toxicity BCG associated cystitis was significantly more frequent than in the mitomycin C group (53.8% versus 39.2%). The combined cystitis OR was 1.81 (95% CI 1.48 to 2.23, p <0.001). The OR for cystitis in the BCG maintenance group did not significantly differ from that in the nonmaintenance therapy group. The results suggest superiority of BCG over mitomycin C for prevention of tumor recurrences in the combined data and particularly in the BCG maintenance treatment subgroup, irrespective of the actual (intermediate or high) tumor risk status. The toxicity with BCG is higher but does not differ between BCG maintenance and nonmaintenance groups.Keywords
This publication has 15 references indexed in Scilit:
- Guidelines on Bladder CancerEuropean Urology, 2002
- A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancerBJU International, 2001
- MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCERJournal of Urology, 2000
- BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)Journal of Urology, 1999
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1996
- Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group studyUrologic Oncology: Seminars and Original Investigations, 1995
- Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the BladderJournal of Urology, 1995
- A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the BladderJournal of Urology, 1993
- Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer: Results of randomized trial after 21 months of follow-upUrology, 1992